Trending...
- New York Young Republican Club Endorses Allen Mashburn For Lieutenant Governor Of North Carolina
- Juneau: Free Parking During Gallery Walk 2023
- Bill Edwards Foundation for the Arts and Ericka Dunlap Collaborate with Local Nonprofits to Celebrate Diversity at Mahaffey
QView's AI-QVCAD, combined with GEHC's ABUS breast ultrasound system, potentially accelerates the acceptance of 3D breast ultrasound as supplemental screening for women with dense breast tissue.
LOS ALTOS, Calif. - AkGlobe -- QView, Inc., a medical technology leader providing artificial intelligence systems for breast cancer detection, and GEHC have signed a distribution agreement where QView Medical's AI-QVCAD software system will be added to GEHC's portfolio of breast imaging AI solutions for the detection and diagnosis of breast cancer.
Under the definitive agreement, GEHC will market and sell AI-QVCAD for its ABUS – Automated Breast Ultrasound System.
"QView working with GEHC is an excellent example of two organizations leveraging our mutual strengths and technological capabilities to provide a multimodality approach for breast screening. There is no single imaging screening solution," said Bob Wang, President, and CEO of QView, Inc
Mammography misses one-third of the cancers in screening women with dense breast tissue; breast density increases women's cancer risk 4-6 times, affecting more than 40 percent of women1. Earlier cancer detection is critical to increased survival rates, improved patient care, and reduced cost of care.
More on AkGlobe News
The ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. Adding AI-QVCAD software to the ABUS system is a powerful tool in detecting breast cancers earlier when they are more treatable, less invasive treatments, and improve patient quality of life.
Clinicians can now review AI-QVCAD results on the Invenia ABUS Viewer, streamlining clinical workflow and reducing the reading time by up to 33%2 while improving clinical outcomes with up to 93%3 sensitivity for lesion detection.
QView Medical supports all efforts to raise awareness of breast density as a significant risk factor - #DENSEBREASTINFO #AREYOUDENSE. QView supports passage of #FINDITEARLY Federal bill requiring health insurers to reimburse for screening and diagnostic breast ultrasound exams – no copay, no deductible.
About QView Medical, Inc.
QView Medical develops AI image-analysis systems for 3D Automated Breast Ultrasound Systems ABUS). The QView team has been the leader in AI technologies and breast cancer detection for over twenty-five years, including developing R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS, and QView AI QVCAD. Visit our website www.qviewmedical.com for more information.
More on AkGlobe News
--
Under the definitive agreement, GEHC will market and sell AI-QVCAD for its ABUS – Automated Breast Ultrasound System.
"QView working with GEHC is an excellent example of two organizations leveraging our mutual strengths and technological capabilities to provide a multimodality approach for breast screening. There is no single imaging screening solution," said Bob Wang, President, and CEO of QView, Inc
Mammography misses one-third of the cancers in screening women with dense breast tissue; breast density increases women's cancer risk 4-6 times, affecting more than 40 percent of women1. Earlier cancer detection is critical to increased survival rates, improved patient care, and reduced cost of care.
More on AkGlobe News
- SSV Network selects Randamu for Distributed Key Generation (DKG) Grant Award
- Lawmato relaunches its virtual consultation app with enhanced features
- MiBOXER Is Exhibiting At Hong Kong International Autumn Lighting Fair
- Beck Properties Group, eXp Realty Expands Service in Southeast Indiana
- Stonely Unleashes Innovative Platform for Homeowners: Design and Order Kitchen Countertops Online with Ease!
The ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. Adding AI-QVCAD software to the ABUS system is a powerful tool in detecting breast cancers earlier when they are more treatable, less invasive treatments, and improve patient quality of life.
Clinicians can now review AI-QVCAD results on the Invenia ABUS Viewer, streamlining clinical workflow and reducing the reading time by up to 33%2 while improving clinical outcomes with up to 93%3 sensitivity for lesion detection.
QView Medical supports all efforts to raise awareness of breast density as a significant risk factor - #DENSEBREASTINFO #AREYOUDENSE. QView supports passage of #FINDITEARLY Federal bill requiring health insurers to reimburse for screening and diagnostic breast ultrasound exams – no copay, no deductible.
About QView Medical, Inc.
QView Medical develops AI image-analysis systems for 3D Automated Breast Ultrasound Systems ABUS). The QView team has been the leader in AI technologies and breast cancer detection for over twenty-five years, including developing R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS, and QView AI QVCAD. Visit our website www.qviewmedical.com for more information.
More on AkGlobe News
- One Million Pages Read in the First Year !!
- Kingston NY-Based Ryan & Ryan Kicks Off its 65th Anniversary Dec. 6 by Underwriting a Chamber of Commerce Mixer Saluting RUPCO
- Tobu Railway's Hosts "Tokyo Downtown Tour: Bamboo Lighting."
- Juneau: Parks & Rec Candy Cane Hunt Returns for the Holidays
- "Street Fighter™ 6" Panel Announced for December 2nd at Los Angeles Comic Con; The Music of Street Fighter 6: A Special Look at the Video Game
--
- Boyd, et al, NEJM Jan 2007
- Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
- Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816
Source: Qview Medical, Inc.
0 Comments
Latest on AkGlobe News
- UnCruise Adventures Welcomes Monica Sagisi as Vice President of Marketing and Sales, Enhancing Small Ship Adventure Offerings
- The Samuel Lawrence Foundation Presents Live from Dubai: First Friday Series Webinar on Dec 1
- Wohler makes the Evertz Quartz Protocol available for their iAM-SUM audio monitors & iVAM-SUM AV monitors
- Genuine Hospitality, LLC Adds Two, Southwest Florida Hotels, to Growing Portfolio
- The CPSE Shenzhen 2023 was inaugurated on October
- Juneau: Free Parking During Gallery Walk 2023
- Bill Edwards Foundation for the Arts and Ericka Dunlap Collaborate with Local Nonprofits to Celebrate Diversity at Mahaffey
- New York Young Republican Club Endorses Allen Mashburn For Lieutenant Governor Of North Carolina
- Diane Gray-Smith Joins STS Capital Partners
- PMUniversity Now Offers Emerging Tech Training As An Authorized Training Partner With Certnexus
- Woburn Dentistry Provides Comprehensive Perio Procedures From One Convenient Location
- Revolutionize Tracking with the iLocate Mini Tracker from Endoacustica Europe!
- Enhancing Residential Living with Air-Driven Home Elevators in Quebec
- Experience the Magic of the Holidays with Fun Corporate Magic's Virtual and In-Person Shows
- Juneau: Thanksgiving weekend schedule for CBJ offices & facilities
- Zeus Investments Korea look at how AI is changing the investment landscape
- Art Exhibition - Mandolene: Hard Edge for a New Generation
- Juneau: Dimond Park Aquatic Center and Field House closing early today, November 20
- Fairbanks: Public Works Update: Snow Plowing Rotational Schedule & General Updates
- Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor